雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片用于难治性良性胃溃疡的疗效

Efficacy of Rabeprazole Enteric-coated Capsules Combined with Hydrotalcite Chewable Tabletsfor Refractory Benign Gastric Ulcer

目的评价雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片对难治性良性胃溃疡的疗效和安全性。方法选取2018年10月~2019年10月在我院诊治的86例难治性良性胃溃疡患者为研究对象,采用随机数字表法分为对照组和观察组,各43例。对照组采用雷贝拉唑肠溶胶囊治疗,观察组在对照组基础上联合铝碳酸镁咀嚼片治疗,比较两组临床治疗总有效率、治疗前后胃溃疡直径、临床症状(腹痛、腹胀、反酸、嗳气)缓解时间以及不良反应发生率。结果观察组临床治疗总有效率为95.34%,高于对照组的81.39%,差异有统计学意义(P<0.05);治疗后两组胃溃疡直径均小于治疗前,且观察组小于对照组,差异有统计学意义(P<0.05);观察组腹痛、腹胀、反酸、嗳气缓解时间均短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片治疗难治性良性胃溃疡效果确切,总有效率高,有助于改善临床症状,促进溃疡愈合,且临床不良反应少,应用安全性良好。

Objective To evaluate the efficacy and safety of rabeprazole enteric-coated capsules combined with hydrotalcite chewable tablets on refractory benign gastric ulcers.Methods 86 patients with refractory benign gastric ulcer who were diagnosed and treated in our hospital from October 2018 to October 2019 were selected as the research objects.They were divided into control group and observation group by random number table method,with 43 cases in each group.The control group was treated with rabeprazole enteric-coated capsules,and the observation group was combined with hydrotalcite chewable tablets on the basis of the control group.The total effective rate of clinical treatment,the diameter of gastric ulcer before and after treatment,and the clinical symptoms(abdominal pain,bloating,regurgitation)were compared between the two groups,acid,belching relief time and incidence of adverse reactions.Results The total effective rate of clinical treatment in the observation group was 95.34%,which was higher than 81.39%in the control group,the difference was statistically significant(P<0.05).After treatment,the diameter of gastric ulcers in the two groups was smaller than before treatment,and the observation group was smaller than the control group,the difference was statistically significant(P<0.05);The relief time of abdominal pain,abdominal distension,acid reflux,and belching in the observation group was shorter than that in the control group,the difference was statistically significant(P<0.05);the difference in the incidence of adverse reactions between the two groups was not statistically significant(P>0.05).Conclusion Rabeprazole enteric-coated capsules combined with hydrotalcite chewable tablets had a definite effect in the treatment of refractory benign gastric ulcers.The total effective rate was high.It was helpful to improve clinical symptoms and promote ulcer healing,with few clinical adverse reactions and good application safety.